TrialAnnals of hematology2025

Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE.

Yuko Mishima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.